CSI Market
Sign In | Register

Fulcrum Therapeutics Inc (FULC) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access FULC quarterly Cash Flow →
The data below summarizes Fulcrum Therapeutics Inc's cash flow activity from Dec 31 2021 to Dec 31 2025, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-74.88
Depreciation & amortization1.39
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation12.47
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Increase Decrease In Deferred Rent And Deferred Lease Incentive-
Increase Decrease In Operating Lease Assets And Liabilities-0.74
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable2.10
Increase (Decrease) in Accounts Payable0.43
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities1.03
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets1.63
Other Working Capital-0.53
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-2.95
Discontinued operations0.00
Net Cash flow from Operating Activities-60.07
Investing Activities
Capital Expenditures-0.31
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities-180.22
Real Estate Investments0.00
Proceeds From Maturity Of Marketable Securities211.25
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities30.72
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock4.17
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-3.85
Payments Of Redeemable Convertible Preferred Stock Issuance Cost-
Restricted Cash Noncurrent1.20
Net Proceeds From Issuances Of Common Stock In Public Offerings-
Proceeds From Issuance Of Common Stock In Connection With Follow On Offering164.50
Cash Paid For Operating Lease Liabilities2.65
Capital Expenditures Incurred But Not Yet Paid-
Issuance Of Common Stock Receivable-
Public Offering Costs Unpaid-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities168.67
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-60.38
Total Cash Flow139.32
4 historic quarters locked

Sign in to unlock the full Fulcrum Therapeutics Inc cash flow history.

Sign In Create Free Account

About Fulcrum Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 24, 2026
  • Source: fulc-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-065197

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License